CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 500 filers reported holding CRISPR THERAPEUTICS AG in Q2 2021. The put-call ratio across all filers is 1.18 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,299,058 | +28.5% | 28,620 | +58.9% | 0.00% | – |
| Q2 2023 | $1,011,246 | +14.4% | 18,013 | -7.8% | 0.00% | – |
| Q1 2023 | $883,791 | -11.2% | 19,540 | -20.2% | 0.00% | -100.0% |
| Q4 2022 | $995,312 | -30.3% | 24,485 | +12.1% | 0.00% | 0.0% |
| Q3 2022 | $1,427,000 | +7.6% | 21,842 | +0.1% | 0.00% | 0.0% |
| Q2 2022 | $1,326,000 | +10.7% | 21,828 | +14.3% | 0.00% | 0.0% |
| Q1 2022 | $1,198,000 | -3.7% | 19,089 | +16.2% | 0.00% | 0.0% |
| Q4 2021 | $1,244,000 | -29.9% | 16,421 | +3.6% | 0.00% | 0.0% |
| Q3 2021 | $1,775,000 | -49.2% | 15,855 | -26.6% | 0.00% | -50.0% |
| Q2 2021 | $3,495,000 | +80.0% | 21,591 | +35.5% | 0.00% | +100.0% |
| Q1 2021 | $1,942,000 | +33.8% | 15,935 | +68.1% | 0.00% | 0.0% |
| Q4 2020 | $1,451,000 | +330.6% | 9,478 | +135.4% | 0.00% | – |
| Q3 2020 | $337,000 | – | 4,026 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $27,989,046 | 33.20% |
| Gilfoyle Management LLC | 100 | $4,842 | 15.90% |
| NEA Management Company, LLC | 1,587,854 | $89,142,124 | 6.80% |
| ARK Investment Management | 7,338,447 | $411,980,394 | 2.73% |
| Nikko Asset Management Americas, Inc. | 3,533,357 | $198,327,328 | 2.09% |
| Del-Sette Capital Management, LLC | 33,661 | $1,889,729 | 1.79% |
| Ikarian Capital, LLC | 200,000 | $11,228,000 | 1.79% |
| Ikarian Capital, LLC | 200,000 | $11,228,000 | 1.79% |
| Merlin Capital, Inc | 8,802 | $494,144 | 1.67% |
| Green Alpha Advisors, LLC | 34,373 | $1,929,700 | 1.27% |